Pedrus Pharma, a University of Wisconsin-Madison spinout that has sped to the finals in the Governor's Business Plan Contest
, may put a stop to the annual flu vaccine hoopla, among other things.
Founders Curtis Brandt and Hansi Dean, both UW-Madison researchers, are developing two drugs based on antiviral peptides discovered in Brandt's lab.......Full article >>>
ration papers were just filed last month."
Pedrus, an acronym of Peptide Drug Strategies, is a drug-discovery company. After taking its first two drugs through trials, it may go on to develop others.
"It turns out that bigger pharmaceutical companies are basically wanting to see a compound get either to the start of phase one or through the phase one clinical ......Full article >>>
st 4-5 years of the company, which we hope will keep the costs down," Brandt said.
The pre-clinical trials, and all of the other development that Pedrus Pharma will be doing with its drug compounds, will need major funding. With eligibility as a company established, Brandt and Dean decided to apply for the Governor's Business Plan Contest because it gave them extra impetus to come up with......Full article >>>
Source:wistechnology.com By Katy Williams 04/18/05Related biology technology :1
. UW-Madison to receive $125M for bioenergy research center2
. Three finalists named for UW-Madison CIO3
. UW-Madison launches new high-speed research network4
. UW-Madison approves new research institute5
. UW-Madison dean predicts bio-economy will fuel Wisconsin6
. Scott Converse, UW-Madison School of Business, on the innovation mind-set7
. Scott Converse, UW-Madison School of Business, on IT workforce development8
. UW-Madisons Beebe wins scientific award9
. UW-Madison MBA program ranked among best for investment return10
. UW-Madison gets $333,000 for biofuels research11
. UW-Madison enters Kauffman grant competition